Saturday 17 October 2026
Export FTH’s income statement to Excel — free account
Faeth Therapeutics, Inc.
In the quarter to June 2026, EPS grew 27.4% and free cash flow fell 174.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.79
1.81
−8.79%
Follow FTH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(70.19%) | (74.01%) | 350.35% | (195.26%) | |
| (59.72%) | (61.78%) | (151.41%) | (176.88%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(112.48%) | (121.61%) | (97.03%) | (109.16%) | |
Free Cash Flow per Share |
(17.56) | (16.03) | (18.46) | (6.00) | |
Free Cash Flow |
(22.15) | (20.22) | (23.90) | (33.86) | |
Capital Expenditures |
0.23 | 0.23 | 0.19 | (0.01) | |
| Other line items | |||||
Cash ROIC |
(46.09%) | (50.83%) | (36.49%) | (9.42%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(556.63) | (405.24) | — | — | |
Operating CF/Net income |
0.93 | 0.97 | 0.13 | 0.17 | |
Depreciation/Fixed assets |
3.89 | 1.70 | 1.96 | 2.80 | |
Capex/Depreciation |
0.54 | 1.68 | 1.39 | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.75) | (16.22) | (18.60) | (6.00) | |
Capex per Share |
0.19 | 0.19 | 0.15 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates